Nitric Oxide, Other

== Dose Adjustments for Adverse Events Delay 1 14 days for initial, second, or third occurrences of quality 3 rash (or quality 2 if intolerable), job application when quality 2 or less and tolerable For the first occurrence of rash leading to delay, job application cetuximab without dose reduction With improvement following a delay for third or second occurrence of rash, job application cetuximab with dosage reduced amount of 50 mg/m2 Discontinue for 4th occurrence of grade 3 rash or any kind of occurrence of grade 4 rash Keep for symptomatic or uncontrolled hypertension, quality 2 proteinuria, quality 3 hemorrhage, thrombosis, thrombocytopenia, or coagulopathy, or quality 3 nonhematologic, noncutaneous adverse event until quality to quality < 1 Discontinue for grade 4 or recurrent grade 3 hemorrhage Completely, grade 4 or recurrent thrombosis, grade 4 hypertension, proteinuria, grade 3 thrombocytopenia lasting > 3 weeks, uncontrolled hypertension lasting > four weeks, fresh grade 2 or worsening of pre-existing arterial thromboembolic event, or any kind of grade 4 nonhematologic, noncutaneous adverse event apart from nausea/vomiting (or grade 3 lasting > 3 weeks) Repeat every 14 days if the neutrophil count number at least 1500/L, platelet count number at least 100,000/L, and had recovered from toxicity related to the prior FOLFOX treatment satisfactorily Reduce 1 dosage level for quality 2 neuropathy persisting between cycles of therapy (without quality during treatment intervals), first/second occurrences of quality 3 neuropathy enduring 1 seven days, as well as for first/second occurrences of quality 3 neuropathy enduring > seven days Discontinue if grade 3 neuropathy persisting between cycles Completely, or grade 4 neuropathy led to permanent discontinuation from the drug Extend infusion duration up to 6 hours for pharyngo-laryngo dysesthesias Repeat every 14 days if the neutrophil count number reaches least 1500/L, platelet count number at least 100,000/L, and had satisfactorily recovered from toxicity related to the prior FOLFOX treatment Quality 34 febrile neutropenia, thrombocytopenia, diarrhea, or mucositis: lower 1 dosage level when resolved to < quality 1 Quality 2 neutropenia, thrombocytopenia, diarrhea, or mucositis on planned day time of therapy: proceed with therapy with 1 dosage level reduction Repeat every 14 days if the neutrophil count number reaches least 1500/L, platelet count number at least 100,000/L, and had satisfactorily recovered from toxicity related to the prior FOLFOX treatment No dosage modifications 5-FU bolus dose/5-FU infusion dose

April 15, 2026 selfscroll

== Dose Adjustments for Adverse Events Delay 1 14 days for initial, second, or third occurrences of quality 3 rash